Impaired coagulation parameters in early rheumatoid arthritis (RA) are restored by effective antirheumatic therapy: a prospective pilot study
Authors' conclusion
Newly diagnosed RA patients have enhanced coagulation activation and impaired fibrinolysis as demonstrated by our results. Effective antirheumatic treatments during the first 24 weeks after diagnosis improved this haemostatic imbalance, with prominent effects of biological drugs and especially tocilizumab, compared with conventional treatment.
Study context
- Population
- Patients with newly diagnosed RA starting MTX
- Participants
- 24 patients
- Exposure
- MTX plus conventional treatment, certolizumab pegol, abatacept or tocilizumab; haemostatic parameters at baseline, 12 and 24 weeks
- Outcome
- Change in haemostatic parameters (OHP, ETP, fibrinogen, F1+2, D-dimer, TAFI, CLT)
- Follow-up
- 24 weeks
Methodological detailsrandomised to treatment arms
- Randomised to treatment arms
Main finding
As reported in the abstract
- Significant reduction in F1+2
- p<0.01
- Significant reduction in fibrinogen
- p<0.01
- Significant reduction in D-dimer
- p<0.01
- Significant reduction in OHP
- p<0.01
- Significant reduction in endogenous thrombin potential (ETP)
- p<0.01
- Significant reduction in clot lysis time (CLT)
- p<0.01
- Significant reduction in thrombin activatable fibrinolysis inhibitor (TAFI)
- p<0.01
- Increase of OFP
- p<0.01
Observational data: associations, not effects.
Further findings
Reduction of OHP by treatment arm · 24 weeks
P Tocilizumab p<0.01 · Certolizumab pegol p<0.01 · Abatacept p=0.25 · Conventional treatment p=0.66
Baseline haemostatic biomarkers vs reference values
- Elevated fibrinogen, F1+2, D-dimer, ETP and OHP vs reference values
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →